|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
A NGF gene therapy trial reduced cognitive decline and stimulated cholinergic fiber growth in humans with mild AD.
|
18986241 |
2008 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
This review will describe: 1) the data from preclinical and clinical studies underlying the rationale of NGF as a potential therapeutic agent for AD; and 2) the alternative strategies to reach adequate concentrations of NGF in relevant brain areas while preventing the onset of adverse effects.
|
18953113 |
2008 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Vitamin D also exerts its effect on AD through nongenomic factors, that is, L-type voltage-sensitive calcium channels, nerve growth factor, the prostaglandins, cyclooxygenase 2, reactive oxygen species, and nitric oxide synthase.
|
22202127 |
2011 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Nerve growth factor therapy has been proposed as a potential means of preventing degeneration of basal forebrain cholinergic neurons in Alzheimer's disease and thereby improving cognition.
|
9878192 |
1998 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
According to genetic studies, Alzheimer's disease (AD) is linked to beta-adrenergic receptor blockade through numerous factors, including human leukocyte antigen genes, the renin-angiotensin system, poly(adenosine diphosphate-ribose) polymerase 1, nerve growth factor, vascular endothelial growth factor, and the reduced form of nicotinamide adenine dinucleotide phosphate.
|
23689075 |
2013 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
These findings also support the safety and feasibility of lentiviral NGF gene transfer for potential testing in human clinical trials to protect degenerating cholinergic neurons in Alzheimer's disease.
|
19013154 |
2009 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Exposure of NGF-producing cells to CSF from AD patients showed significantly reduced NGF-release as compared to CSF from LBD or SCI patients.
|
30092220 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Asparagus cochinchinensis stimulates release of nerve growth factor and abrogates oxidative stress in the Tg2576 model for Alzheimer's disease.
|
29625607 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Nerve growth factor (NGF) is a potential therapeutic agent for Alzheimer's disease (AD) as it has positive effects on the basal forebrain cholinergic neurons whose degeneration correlates with the cognitive decline in AD.
|
22113314 |
2012 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
The multifactorial causes of AD offer a variety of possible targets for gene therapy, including two neurotrophic growth factors, nerve growth factor and brain-derived neurotrophic factor, Abeta-degrading enzymes, such as neprilysin, endothelin-converting enzyme and cathepsin B, and AD associated apolipoprotein E. This review also discusses advantages and drawbacks of various rapidly developing virus-mediated gene delivery techniques for gene therapy.
|
20158567 |
2010 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
These results, taken in conjunction with the reduced choline acetyltransferase activity and our previously published data showing a loss of high affinity nerve growth factor binding in both the dorsal and the ventral striatum of patients with Alzheimer's disease, indicate that receptor loss and the consequent decrease in trophic support may be associated with the degeneration of cholinergic neurons during Alzheimer's disease.
|
9184126 |
1997 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Despite the need for further testing, their report illustrated a mild but significant therapeutic benefit of NGF for the treatment of AD and provided important data concerning the safety and efficacy of ex vivo gene therapy in humans.
|
16144466 |
2005 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
A total of 170 studies were included in the meta-analysis and systematic review, which demonstrated increased peripheral levels of high-sensitivity C reactive protein (Hedges's g 0.281, p<0.05), interleukin-6 (IL-6) (0.429, p<0.005), soluble tumour necrosis factor receptor 1 (sTNFR1) (0.763, p<0.05), soluble tumour necrosis factor receptor 2 (sTNFR2) (0.354, p<0.005), alpha1-antichymotrypsin (α1-ACT) (1.217, p<0.005), IL-1β (0.615, p<0.05) and soluble CD40 ligand (0.868, p<0.005), and CSF levels of IL-10 (0.434, p<0.05), monocyte chemoattractant protein-1 (MCP-1) (0.798, p<0.005), transforming growth factor-beta 1 (1.009, p<0.05), soluble triggering receptor expressed on myeloid cells2 (sTREM2) (0.587, p<0.001), YKL-40 (0.849, p<0.001), α1-ACT (0.638, p<0.001), nerve growth factor (5.475, p<0.005) and visinin-like protein-1 (VILIP-1) (0.677, p<0.005), in AD compared with the control.
|
30630955 |
2019 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Thus, small but reproducible increases in NGF protein reported in AD cortex do not result from increases in NGF mRNA.
|
8915599 |
1996 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Therefore, to identify effective therapeutic agents for AD, we investigated the neuroprotective effects of two naturally occurring retinoid X receptor (RXR) agonists (SPF1 and SPF2), isolated from the root of Sophora tonkinensis Gagnep., on the Aβ<sub>25-35</sub>-induced cytotoxicity against nerve growth factor-differentiated rat pheochromocytoma (PC12) cells.
|
30377903 |
2019 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
While the use of NGF for the treatment of the cholinergic deficits present in Alzheimer's disease shows promise based on its efficacy in animal models, concerns about side-effects of intraventricular NGF delivery in humans have been raised.
|
9918705 |
1999 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) models were established by injecting Aβ(1-42) into the rat hippocampus and the effects of learning and memory were observed by a Morris water maze test, immunohistological alterations, and correlative indicators covering nerve growth (brain-derived neurotrophic factor, glial-cell-derived trophic factor, and nerve growth factor), interleukin 1β, tumor necrosis factor, superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), malondialdehyde (MDA), glial fibrillary acidic protein (GFAP), and microglial CD11b in AD rats.
|
29714500 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Nerve Growth Factor (NGF) is being considered as a therapeutic candidate for Alzheimer's disease.
|
28163105 |
2017 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
In summary, we hope to describe the experimental and clinical data demonstrating the important roles of NGF for AD treatment.
|
26801170 |
2016 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
These combined effects on NGF metabolism would explain the well-known cholinergic atrophy found in Alzheimer's disease and would offer new therapeutic opportunities aimed at correcting the NGF dysmetabolism along with Abeta-induced inflammatory responses.
|
19680822 |
2010 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Therefore, treatments with NGF could ameliorate cortical cholinergic dysfunction in AD.
|
9775403 |
1998 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
The present findings suggested that BMSC provided an effective carrier for delivery of NGF into AD rats, and the administration of NGF-gene-modified BMSC may be considered as a potential strategy for the development of effective therapies for the treatment of AD.
|
18074108 |
2008 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease.
|
25676388 |
2015 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
The cholinotrophic system, which is dependent upon nerve growth factor and its receptors for survival, is selectively vulnerable in Alzheimer's disease (AD).
|
20937383 |
2011 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
The delivery of NGF by gene transfer to the brain merits further study as a means of preventing cholinergic neuronal degeneration in human disorders such as Alzheimer's disease.
|
8732162 |
1996 |